Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations

Authors: Anjali B. Daniel, Vrinda Saraff, Nick J. Shaw, Robert Yates, M. Zulf Mughal, Raja Padidela

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Hypophosphatasia (HPP) is a rare, heterogeneous disease caused by low tissue-nonspecific alkaline phosphatase activity and associated with a range of signs and symptoms, including bone mineralization defects, respiratory problems, seizures, premature tooth loss, and fractures. Data from patients with HPP and their healthcare resource utilization are lacking. We evaluated healthcare utilization for 3 patients with differing severities of HPP.

Results

Patient 1 had perinatal HPP (received enzyme replacement therapy asfotase alfa under a compassionate use program), Patient 2 had infantile HPP, and Patient 3 had childhood HPP. Healthcare resources used in the National Health Service, England, were identified from coded activities in the hospital database and detailed medical records. These data showed that healthcare utilization was directly related to disease severity. Patient 1 had respiratory complications necessitating prolonged admission for ventilation from birth. Over 2.5 years, this patient was hospitalized 725 days, with visits from 16 specialists. Patient 2 had HPP-associated signs and symptoms starting in infancy, was treated for craniosynostosis, experienced multiple fractures, and required outpatient management for > 18 years. Patient 3 developed signs and symptoms of HPP in childhood and received outpatient and day case treatment for dental, orthopedic, and cardiovascular problems over 24 years. Healthcare utilization varied with severity and complexity of disease manifestations between these patients.

Conclusions

With the recent approval of asfotase alfa for HPP, data from this analysis may help mobilize multidisciplinary healthcare resources for management of HPP by elucidating healthcare resource needs of patients who show a spectrum of clinical manifestations of HPP.
Literature
1.
go back to reference Weiss MJ, Cole DE, Ray K, Whyte MP, Lafferty MA, Mulivor RA, et al. A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci U S A. 1988;85:7666–9.CrossRefPubMedPubMedCentral Weiss MJ, Cole DE, Ray K, Whyte MP, Lafferty MA, Mulivor RA, et al. A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci U S A. 1988;85:7666–9.CrossRefPubMedPubMedCentral
2.
go back to reference Whyte MP. Hypophosphatasia and how alkaline phosphatase promotes mineralization. In: Thakker RV, Whyte MP, Eisman JA, Igarashi T, editors. Genetics of bone biology and skeletal disease. 2nd ed. San Diego, CA: Elsevier (Academic Press); 2018;481-504 Whyte MP. Hypophosphatasia and how alkaline phosphatase promotes mineralization. In: Thakker RV, Whyte MP, Eisman JA, Igarashi T, editors. Genetics of bone biology and skeletal disease. 2nd ed. San Diego, CA: Elsevier (Academic Press); 2018;481-504
3.
go back to reference Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(Suppl 2):380–8.PubMed Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(Suppl 2):380–8.PubMed
5.
go back to reference Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B. A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet. 2011;75:439–45.CrossRefPubMed Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B. A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet. 2011;75:439–45.CrossRefPubMed
7.
go back to reference Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212:901–3.CrossRefPubMed Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212:901–3.CrossRefPubMed
8.
10.
go back to reference Baumgartner-Sigl S, Haberlandt E, Mumm S, Scholl-Burgi S, Sergi C, Ryan L, et al. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone. 2007;40:1655–61.CrossRefPubMed Baumgartner-Sigl S, Haberlandt E, Mumm S, Scholl-Burgi S, Sergi C, Ryan L, et al. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone. 2007;40:1655–61.CrossRefPubMed
11.
go back to reference Whyte MP, Mahuren JD, Vrabel LA, Coburn SP. Markedly increased circulating pyridoxal-5′-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest. 1985;76:752–6.CrossRefPubMedPubMedCentral Whyte MP, Mahuren JD, Vrabel LA, Coburn SP. Markedly increased circulating pyridoxal-5′-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest. 1985;76:752–6.CrossRefPubMedPubMedCentral
12.
go back to reference Barvencik F, Beil FT, Gebauer M, Busse B, Koehne T, Seitz S, et al. Skeletal mineralization defects in adult hypophosphatasia—a clinical and histological analysis. Osteoporos Int. 2011;22:2667–75.CrossRefPubMed Barvencik F, Beil FT, Gebauer M, Busse B, Koehne T, Seitz S, et al. Skeletal mineralization defects in adult hypophosphatasia—a clinical and histological analysis. Osteoporos Int. 2011;22:2667–75.CrossRefPubMed
13.
go back to reference Collmann H, Mornet E, Gattenlohner S, Beck C, Girschick H. Neurosurgical aspects of childhood hypophosphatasia. Childs Nerv Syst. 2009;25:217–23.CrossRefPubMed Collmann H, Mornet E, Gattenlohner S, Beck C, Girschick H. Neurosurgical aspects of childhood hypophosphatasia. Childs Nerv Syst. 2009;25:217–23.CrossRefPubMed
14.
go back to reference Berkseth KE, Tebben PJ, Drake MT, Hefferan TE, Jewison DE, Wermers RA. Clinical spectrum of hypophosphatasia diagnosed in adults. Bone. 2013;54:21–7.CrossRefPubMed Berkseth KE, Tebben PJ, Drake MT, Hefferan TE, Jewison DE, Wermers RA. Clinical spectrum of hypophosphatasia diagnosed in adults. Bone. 2013;54:21–7.CrossRefPubMed
15.
go back to reference Coe JD, Murphy WA, Whyte MP. Management of femoral fractures and pseudofractures in adult hypophosphatasia. J Bone Joint Surg Am. 1986;68:981–90.CrossRefPubMed Coe JD, Murphy WA, Whyte MP. Management of femoral fractures and pseudofractures in adult hypophosphatasia. J Bone Joint Surg Am. 1986;68:981–90.CrossRefPubMed
16.
go back to reference Beck C, Morbach H, Wirth C, Beer M, Girschick HJ. Whole-body MRI in the childhood form of hypophosphatasia. Rheumatol Int. 2011;31:1315–20.CrossRefPubMed Beck C, Morbach H, Wirth C, Beer M, Girschick HJ. Whole-body MRI in the childhood form of hypophosphatasia. Rheumatol Int. 2011;31:1315–20.CrossRefPubMed
17.
go back to reference Kozlowski K, Sutcliffe J, Barylak A, Harrington G, Kemperdick H, Nolte K, et al. Hypophosphatasia. Review of 24 cases. Pediatr Radiol. 1976;5:103–17.CrossRefPubMed Kozlowski K, Sutcliffe J, Barylak A, Harrington G, Kemperdick H, Nolte K, et al. Hypophosphatasia. Review of 24 cases. Pediatr Radiol. 1976;5:103–17.CrossRefPubMed
18.
go back to reference Moulin P, Vaysse F, Bieth E, Mornet E, Gennero I, Dalicieux-Laurencin S, et al. Hypophosphatasia may lead to bone fragility: don’t miss it. Eur J Pediatr. 2009;168:783–8.CrossRefPubMed Moulin P, Vaysse F, Bieth E, Mornet E, Gennero I, Dalicieux-Laurencin S, et al. Hypophosphatasia may lead to bone fragility: don’t miss it. Eur J Pediatr. 2009;168:783–8.CrossRefPubMed
19.
go back to reference Silver MM, Vilos GA, Milne KJ. Pulmonary hypoplasia in neonatal hypophosphatasia. Pediatr Pathol. 1988;8:483–93.CrossRefPubMed Silver MM, Vilos GA, Milne KJ. Pulmonary hypoplasia in neonatal hypophosphatasia. Pediatr Pathol. 1988;8:483–93.CrossRefPubMed
20.
go back to reference Teber S, Sezer T, Kafali M, Kenderli T, Siklar Z, Berberoglu M, et al. Hypophosphatasia associated with pseudotumor cerebri and respiratory insufficiency. Indian J Pediatr. 2008;75:186–8.CrossRefPubMed Teber S, Sezer T, Kafali M, Kenderli T, Siklar Z, Berberoglu M, et al. Hypophosphatasia associated with pseudotumor cerebri and respiratory insufficiency. Indian J Pediatr. 2008;75:186–8.CrossRefPubMed
21.
go back to reference Balasubramaniam S, Bowling F, Carpenter K, Earl J, Chaitow J, Pitt J, et al. Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5′-phosphate availability. J Inherit Metab Dis. 2010;33(Suppl 3):S25–33.CrossRefPubMed Balasubramaniam S, Bowling F, Carpenter K, Earl J, Chaitow J, Pitt J, et al. Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5′-phosphate availability. J Inherit Metab Dis. 2010;33(Suppl 3):S25–33.CrossRefPubMed
22.
go back to reference Schmidt T, Mussawy H, Rolvien T, Hawellek T, Hubert J, Ruther W, et al. Clinical, radiographic and biochemical characteristics of adult hypophosphatasia. Osteoporos Int. 2017;28:2653–62.CrossRefPubMed Schmidt T, Mussawy H, Rolvien T, Hawellek T, Hubert J, Ruther W, et al. Clinical, radiographic and biochemical characteristics of adult hypophosphatasia. Osteoporos Int. 2017;28:2653–62.CrossRefPubMed
23.
go back to reference Mohn A, De Leonibus C, de Giorgis T, Mornet E, Chiarelli F. Hypophosphatasia in a child with widened anterior fontanelle: lessons learned from late diagnosis and incorrect treatment. Acta Paediatr. 2011;100:e43–6. Mohn A, De Leonibus C, de Giorgis T, Mornet E, Chiarelli F. Hypophosphatasia in a child with widened anterior fontanelle: lessons learned from late diagnosis and incorrect treatment. Acta Paediatr. 2011;100:e43–6.
26.
27.
go back to reference Reibel A, Maniere MC, Clauss F, Droz D, Alembik Y, Mornet E, et al. Orodental phenotype and genotype findings in all subtypes of hypophosphatasia. Orphanet J Rare Dis. 2009;4:6.CrossRefPubMedPubMedCentral Reibel A, Maniere MC, Clauss F, Droz D, Alembik Y, Mornet E, et al. Orodental phenotype and genotype findings in all subtypes of hypophosphatasia. Orphanet J Rare Dis. 2009;4:6.CrossRefPubMedPubMedCentral
28.
go back to reference Whyte MP, Zhang F, Wenkert D, McAlister WH, Mack KE, Benigno MC, et al. Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone. 2015;75:229–39.CrossRefPubMed Whyte MP, Zhang F, Wenkert D, McAlister WH, Mack KE, Benigno MC, et al. Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone. 2015;75:229–39.CrossRefPubMed
29.
go back to reference Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12:233–46.CrossRefPubMed Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12:233–46.CrossRefPubMed
30.
go back to reference Weber TJ, Sawyer EK, Moseley S, Odrljin T, Kishnani PS. Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys. Metabolism. 2016;65:1522–30.CrossRefPubMed Weber TJ, Sawyer EK, Moseley S, Odrljin T, Kishnani PS. Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys. Metabolism. 2016;65:1522–30.CrossRefPubMed
31.
go back to reference Lopez-Bastida J, Oliva-Moreno J. Cost of illness and economic evaluation in rare diseases. Adv Exp Med Biol. 2010;686:273–82.CrossRefPubMed Lopez-Bastida J, Oliva-Moreno J. Cost of illness and economic evaluation in rare diseases. Adv Exp Med Biol. 2010;686:273–82.CrossRefPubMed
32.
go back to reference Angelis A, Kanavos P, Lopez-Bastida J, Linertova R, Nicod E, Serrano-Aguilar P. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res. 2015;15:428.CrossRefPubMedPubMedCentral Angelis A, Kanavos P, Lopez-Bastida J, Linertova R, Nicod E, Serrano-Aguilar P. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res. 2015;15:428.CrossRefPubMedPubMedCentral
33.
go back to reference Bradley JM, Blume SW, Balp MM, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J. 2013;41:571–7.CrossRefPubMed Bradley JM, Blume SW, Balp MM, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J. 2013;41:571–7.CrossRefPubMed
34.
go back to reference Cavazza M, Kodra Y, Armeni P, De Santis M, Lopez-Bastida J, Linertova R, et al. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Eur J Health Econ. 2016;17(Suppl 1):19–29.CrossRefPubMed Cavazza M, Kodra Y, Armeni P, De Santis M, Lopez-Bastida J, Linertova R, et al. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Eur J Health Econ. 2016;17(Suppl 1):19–29.CrossRefPubMed
36.
go back to reference Strensiq [package insert]. Boston: Alexion Pharmaceuticals, Inc.; 2018. Strensiq [package insert]. Boston: Alexion Pharmaceuticals, Inc.; 2018.
37.
go back to reference Strensiq [summary of product characteristics]. Rueil-Malmaison: Alexion Europe; 2017. Strensiq [summary of product characteristics]. Rueil-Malmaison: Alexion Europe; 2017.
38.
go back to reference Strensiq Australia [package insert]. Frenchs Forest NSW Australia: Alexion Pharmaceuticals Australasia; 2016. Strensiq Australia [package insert]. Frenchs Forest NSW Australia: Alexion Pharmaceuticals Australasia; 2016.
39.
go back to reference Strensiq [prescribing information]. Tokyo: Alexion Pharma GK; 2015. Strensiq [prescribing information]. Tokyo: Alexion Pharma GK; 2015.
40.
go back to reference Whyte MP, Wenkert D, McAlister WH, Mughal MZ, Freemont AJ, Whitehouse R, et al. Chronic recurrent multifocal osteomyelitis mimicked in childhood hypophosphatasia. J Bone Miner Res. 2009;24:1493–505.CrossRefPubMed Whyte MP, Wenkert D, McAlister WH, Mughal MZ, Freemont AJ, Whitehouse R, et al. Chronic recurrent multifocal osteomyelitis mimicked in childhood hypophosphatasia. J Bone Miner Res. 2009;24:1493–505.CrossRefPubMed
41.
go back to reference Bayley N. Bayley scales of infant and toddler development. Administration Manual. 3rd ed. San Antonio: Pearson; 2006. Bayley N. Bayley scales of infant and toddler development. Administration Manual. 3rd ed. San Antonio: Pearson; 2006.
42.
go back to reference Folio MR, Fewell RR. Peabody developmental motor scales. 2nd ed. Austin: Pro-Ed Inc.; 2000. Folio MR, Fewell RR. Peabody developmental motor scales. 2nd ed. Austin: Pro-Ed Inc.; 2000.
43.
go back to reference Deitz JC, Kartin D, Kopp K. Review of the Bruininks-Oseretsky test of motor proficiency, second edition (BOT-2). Phys Occup Ther Pediatr. 2007;27:87–102.CrossRefPubMed Deitz JC, Kartin D, Kopp K. Review of the Bruininks-Oseretsky test of motor proficiency, second edition (BOT-2). Phys Occup Ther Pediatr. 2007;27:87–102.CrossRefPubMed
44.
go back to reference Whyte MP, Greenberg CR, Salman NJ, Madson K, Mhanni A, Weber TJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366:904–13.CrossRefPubMed Whyte MP, Greenberg CR, Salman NJ, Madson K, Mhanni A, Weber TJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366:904–13.CrossRefPubMed
45.
go back to reference Whyte MP, Madson KL, Phillips D, Reeves A, McAlister WH, Yakimoski A, et al. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight. 2016;1:e85971.CrossRefPubMedPubMedCentral Whyte MP, Madson KL, Phillips D, Reeves A, McAlister WH, Yakimoski A, et al. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight. 2016;1:e85971.CrossRefPubMedPubMedCentral
Metadata
Title
Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations
Authors
Anjali B. Daniel
Vrinda Saraff
Nick J. Shaw
Robert Yates
M. Zulf Mughal
Raja Padidela
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0869-4

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue